Formulation design for children: where to begin?
Start with consideration of the intended therapeutic effect.
Decide what shape do you need the plasma concentration vs time profile to be?
How old are paediatric patients?
Anywhere from zero to 18 years!
Neonate - 0-27 days Infant - 1-23 months Child - 2-11 years Adolescent - 12-18 years Adult - >18 years
The formulation type you select will depend on a combination of factors. These are:
Pharmaceutical factors:
Biopharmaceutics:
The study of the factors influencing the bioavailability of drug in man and the use of this information to optimise pharmacologic or therapeutic activity of drug products in clinical applications.
Factors influencing bioavailability:
PK and absorption differences in children?
Changes occur in:
Differences in the GI tract (dissolution) ?
Differences in the GI tract (transit)?
Differences in the GI tract (permeability)?
Differences in the GI tract (metabolism)?
Gut wall–> CYP3A: expressed in all children over 6 months and half of those <6 months based on biopsy data
Hepatic –> CYPs generally present from birth and reach adult levels at 2-5 years depending on isoform
UGTs reach adult levels at different ages depending on isoform (anywhere between <2yrs and 18 years)
Children generally have a larger liver size and hepatic blood flow per body weight than adults
Formulation bridging?
Formulation bridging – assessing the rate and extent of absorption from one formulation vs another.
i.e. if I switch between these two products, will I get the same Cmax and AUC?
What is relative bioavailability?
Comparing Cmax and AUC between two products
Bioequivalence definiton:
Assessing statistical equivalence of Cmax and AUC from two different products using a confidence intervals approach (regulatory standard)
Why do we need formulation bridging for paediatrics?
Paediatric formulation bridging - how?
Relative bioavailability study
In vitro testing
If a solution and tablet are bioequivalent in adults, will they also be equivalent in children?
Not always
–> Smaller volumes for dissolution, different gastric pH etc. may lead to a different result depending on what the important factors are for drug absorption from the tablet
What is in silico PBPK modelling?
Physiologically based pharmacokinetic modelling.
A key tool to help put all of the pieces together and work out what the overall impact on formulation performance
Mechanistically simulates the processes involved in absorption and PK performance
Food can affect formulation performance and drug absorption in a number of ways:
Peadiatric patients will eat differently to adult patients.
Mixing paediatric medicines with food:
Why solid dosage form?
Definition of friability?
is the tendency for a tablet to chip, crumble or break following compression
Definition of crushing force?
the force required to break the tablet along a given axis
Definition of tensile strength ?
the stress required to induce flow in the material.
Definition of hardness:
the resistance of a material to a permanent shape change such as resistance to scratching or indentation.